Nnit A/s · OMXCOP:NNIT
Nnit A/s — Merger or Acquisition (April 2019)
11 slides from Nnit A/s's merger presentation, Apr 24, 2019
Slide 1: Acquisition of Halfmann Goetsch Partner AG (HGP)
Acquisition of Halfmann Goetsch Partner AG (HGP) April 24, 2019
Slide 2: The NNIT Presenting Team
The NNIT Presenting Team CARSTEN KROGSGAARD KLAUS HOSBOND SKOVRUP THOMSEN Chief Financial Officer Head of Investor Relations 2 Classification Public Author TRUC Approved by CKTH Version 1.0
Slide 3: Forward looking statements
Forward looking statements This presentation contains forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘outlook’, ‘guidance’, ‘target’ and other words and terms of similar me
Slide 4: Acquisition of HGP
Acquisition of HGP • As communicated in the updated strategy NNIT is open to bolt on acquisitions in order to scale and accelerate the growth of our international Life Sciences business • HGP is a highly specialized service provider for IT compliance and quality management to the life sciences indus
Slide 5: HGP is present in major life sciences hubs
HGP is present in major life sciences hubs German office Frankfurt am Main, Germany Headquarters Polish office Basel, Switzerland Krakow, Poland Asia Pacific office Singapore Indonesian office Jakarta, Indonesia 70+ employees
Slide 6: Transaction overview
Transaction overview • An upfront payment of CHF 8.55m paid in cash • An earn-out target of CHF 2.85m (100% target realization) with an earn-out range of 0-135% of target depending on performance in gross profit for the combined operation of HGP and NNIT Life Sciences Europe Transaction • • Earn-out
Slide 7: We are acquiring HGP to further boost international life sciences
We are acquiring HGP to further boost international life sciences Business overview Financials* • Swiss-based consultancy business, CHFm +14% 10 9.0 50% Halfmann Goetsch Partner established in 8.6 8 7.6 0.7 40% 2008 5.9 • Employs 70+ experts with extensive 6 30% experience in the life sciences indus
Slide 8: How does the transaction create value?
How does the transaction create value? • Strengthens NNIT’s presence across a global Industry Associations Contributions pharma and biotech client portfolio • Enhances our joint ability to provide end-to-end life ISPE and GAMP sciences transformational IT services • HGP consultants have conducted va
Slide 9: The European Life Sciences IT markets
The European Life Sciences IT markets • Life sciences companies have traditionally been Growth in European Life Sciences market (USDm) slow to adopt digital transformation, but are +36% expected to accelerate with an increased focus on digitization in Regulatory Affairs, Clinical 5,223 5,532 5,733 5
Slide 10: Outlook
Outlook 2019 Previous guidance Revenue Constant currencies: 3-6% Constant currencies: 3-6% growth* Reported currencies: 0.6pp higher Reported currencies: 0.3pp higher Operating Constant currencies: 10-10.5% Constant currencies: 10-10.5% margin Reported currencies: 0.4pp lower Reported currencies: 0.
Slide 11: Investor contact information
Investor contact information Upcoming events Investor contact May 14, 2019: • Interim report for the first three months of 2019 August 14, 2019: • Interim report for the first six months of 2019 October 24, 2019: • Interim report for the first nine months of 2019 KLAUS HOSBOND SKOVRUP Head of Invest